XML 77 R56.htm IDEA: XBRL DOCUMENT v3.6.0.2
Collaborations (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2014
Oct. 31, 2013
Dec. 31, 2009
Jun. 30, 2001
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
[8]
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Oct. 01, 2015
Collaboration and other revenue                               $ 833.7 $ 808.1 $ 788.4  
Revenue           $ 5,760.5 $ 5,191.7 $ 5,404.8 $ 4,865.1 $ 5,375.6 $ 4,959.7 $ 4,978.7 $ 4,644.7     21,222.1 19,958.7 19,615.6  
Other Nonoperating Income (Expense)                               195.6 341.5 368.3  
Research and Development Expense                               5,243.9 4,796.4 4,733.6  
Other-net, (income) expense           15.8 27.2 21.2 (149.0) 44.7 86.5 (123.3) 92.7     (84.8) 100.6 340.5  
Marketing, selling, and administrative                               6,452.0 6,533.0 6,620.8  
Acquired in-process research and development           30.0 $ 0.0 $ 0.0 0.0 $ 199.0 $ 0.0 $ 80.0 256.0     30.0 535.0 200.2  
Amortization of Intangible Assets                               687.9 631.8 535.9  
Erbitux API [Member]                                      
Sales Revenue, Goods, Net                               0.0 23.3 46.1  
Erbitux [Member]                                      
Sales Revenue, Goods, Net                               587.0 152.3 0.0  
Collaboration and other revenue                               100.0 309.4 327.2  
Revenue                               687.0 485.0 373.3  
Trajenta (BI) [Member]                                      
Collaboration and other revenue                               436.6 356.8 328.8  
Effient [Member]                                      
Sales Revenue, Goods, Net                               535.2 523.0 522.2  
BI compounds [Member]                                      
Other-net, (income) expense                                   92.0  
LLY compounds [Member]                                      
Acquired in-process research and development                           $ 55.2          
Tanezumab [Member]                                      
Acquired in-process research and development                         $ 200.0            
Jardiance (BI) [Member]                                      
Collaboration and other revenue                               201.9 60.2 0.0  
Basaglar [Member]                                      
Sales Revenue, Goods, Net                               86.1 11.1 0.0  
United States [Member]                                      
Revenue [1]                               11,506.2 10,097.4 9,134.1  
Milestone Payments, Sales-based [Member] | Baricitinib [Member]                                      
Collaborative Arrangement, Rights and Obligations, Terms     $ (150.0)                                
Milestone Payments, Sales-based [Member] | Tanezumab [Member]                                      
Collaborative Arrangement, Rights and Obligations, Terms   $ (1,230.0)                                  
Milestone Payments, Development and Regulatory, Capitalized [Member] | Trajenta (BI) [Member]                                      
Collaborative Arrangement, Rights and Obligations, Terms [2],[3]                               0.0 0.0 0.0  
Milestone Payments, Development and Regulatory, Capitalized [Member] | Jardiance [Member]                                      
Collaborative Arrangement, Rights and Obligations, Terms [4]                               0.0 0.0 (299.5)  
Milestone Payments, Development and Regulatory, Capitalized [Member] | LLY compounds [Member]                                      
Collaborative Arrangement, Rights and Obligations, Terms [2]                               187.5 0.0 62.5  
Milestone Payments, Development and Regulatory, Capitalized [Member] | Baricitinib [Member] | Subsequent Event [Member]                                      
Collaborative Arrangement, Rights and Obligations, Terms         $ (65.0)                            
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | Trajenta (BI) [Member]                                      
Collaborative Arrangement, Rights and Obligations, Terms [2],[3],[5]                               (446.4)      
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | Jardiance [Member]                                      
Collaborative Arrangement, Rights and Obligations, Terms [2],[4],[5]                               (299.5)      
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | LLY compounds [Member]                                      
Collaborative Arrangement, Rights and Obligations, Terms [2],[5]                               $ 250.0      
Profit And Development And Marketing Share [Member] | Effient [Member]                                      
Collaborative Arrangement, Rights and Obligations Percent       50.00%                              
Sales Reported [Member] | Erbitux [Member]                                      
Collaborative Arrangement, Rights and Obligations Percent                               38.00%      
Research And Development Exp [Member] | Baricitinib [Member]                                      
Collaborative Arrangement, Rights and Obligations Percent     30.00%                                
Milestone Payments, Development and Regulatory, Expensed [Member] | Baricitinib [Member]                                      
Research and Development Expense                 $ 55.0                    
Milestone Payments, Development and Regulatory [Member] | Baricitinib [Member]                                      
Collaborative Arrangement, Rights and Obligations, Terms     $ (295.0)                                
Milestone Payments, Development and Regulatory [Member] | Tanezumab [Member]                                      
Collaborative Arrangement, Rights and Obligations, Terms   $ (350.0)                                  
Milestone Payments, Development and Regulatory [Member] | BACE (AZ) Inhibitor [Member]                                      
Research and Development Expense                               $ 100.0      
Collaborative Arrangement, Rights and Obligations, Terms $ (350.0)                                    
Milestone Payments, Development and Regulatory, First Indication [Member] | Baricitinib [Member]                                      
Collaborative Arrangement, Rights and Obligations, Terms     $ (115.0)                                
Royalty Payments Received [Member] | Baricitinib [Member]                                      
Collaborative Arrangement, Rights and Obligations Percent     20.00%                                
Collaborative Arrangement [Member]                                      
Marketing, selling, and administrative                               $ 194.9 213.2 $ 211.2  
Erbitux Acquisition [Member]                                      
Business Acquisition, Pro Forma Revenue                                 20,200.0    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles [6]                                     $ 602.1
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Noncurrent                                     232.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent                                     (228.2)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets                                     57.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net                                     663.3
Business Combination, Contingent Consideration, Liability [7]                                     $ (663.3)
Erbitux Acquisition [Member] | Erbitux [Member]                                      
Business Acquisition, Pro Forma Revenue                                 $ 735.0    
AstraZeneca [Member]                                      
Acquired in-process research and development           $ 30.0                 $ 50.0        
[1] (1) Revenue is attributed to the countries based on the location of the customer.
[2] (1) In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales.
[3] (2) Jentadueto is included in the Trajenta family of product results.
[4] (3) Glyxambi and Synjardy are included in the Jardiance family of product results.
[5] (4) The cumulative amount represents the total initial amounts that were (deferred) or capitalized from the start of this collaboration through the end of the reporting period.
[6] (1) These intangible assets are being amortized to cost of sales using the straight-line method through the co-development period in North America as set forth in the original agreement, which was scheduled to expire in September 2018.
[7] (2) See Note 7 for discussion on the estimation of the contingent consideration liability.
[8] (3) See Note 4 for additional information on our collaboration with AstraZeneca related to this oral beta-secretase cleaving enzyme (BACE) inhibitor.